CN101690729A - Application of montmorillonite in preparing medicament - Google Patents
Application of montmorillonite in preparing medicament Download PDFInfo
- Publication number
- CN101690729A CN101690729A CN200910308592A CN200910308592A CN101690729A CN 101690729 A CN101690729 A CN 101690729A CN 200910308592 A CN200910308592 A CN 200910308592A CN 200910308592 A CN200910308592 A CN 200910308592A CN 101690729 A CN101690729 A CN 101690729A
- Authority
- CN
- China
- Prior art keywords
- montmorillonitum
- montmorillonite
- cold
- influenza
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 30
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 title abstract description 18
- 229910052901 montmorillonite Inorganic materials 0.000 title abstract description 18
- 239000007921 spray Substances 0.000 claims abstract description 26
- 239000002552 dosage form Substances 0.000 claims abstract description 16
- 239000000443 aerosol Substances 0.000 claims abstract description 15
- 239000007923 nasal drop Substances 0.000 claims description 51
- 238000002360 preparation method Methods 0.000 claims description 31
- 230000002265 prevention Effects 0.000 claims description 22
- 229940124579 cold medicine Drugs 0.000 claims description 3
- 206010022000 influenza Diseases 0.000 abstract description 37
- 241000700605 Viruses Species 0.000 abstract description 26
- 210000002345 respiratory system Anatomy 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 201000009240 nasopharyngitis Diseases 0.000 abstract description 10
- 230000003405 preventing effect Effects 0.000 abstract description 10
- 230000008901 benefit Effects 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 206010052804 Drug tolerance Diseases 0.000 abstract 1
- 231100000956 nontoxicity Toxicity 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 23
- 241001500351 Influenzavirus A Species 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 241000712461 unidentified influenza virus Species 0.000 description 13
- 239000007922 nasal spray Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241000725643 Respiratory syncytial virus Species 0.000 description 10
- 230000003203 everyday effect Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 208000036142 Viral infection Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 208000037797 influenza A Diseases 0.000 description 8
- 210000003928 nasal cavity Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 6
- 230000009849 deactivation Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229960000329 ribavirin Drugs 0.000 description 5
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 5
- 229910021647 smectite Inorganic materials 0.000 description 5
- 230000001018 virulence Effects 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- 206010039101 Rhinorrhoea Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 208000010753 nasal discharge Diseases 0.000 description 4
- 210000002850 nasal mucosa Anatomy 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 210000001331 nose Anatomy 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 241000712431 Influenza A virus Species 0.000 description 3
- 241000713196 Influenza B virus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010028748 Nasal obstruction Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000012930 cell culture fluid Substances 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000037798 influenza B Diseases 0.000 description 3
- 238000003801 milling Methods 0.000 description 3
- 229940100662 nasal drops Drugs 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- KVYRCBOUKXJXDK-UHFFFAOYSA-N 3,4-dimethylphenazine-1,2-diamine hydrochloride Chemical compound Cl.C1=CC=CC2=NC3=C(C)C(C)=C(N)C(N)=C3N=C21 KVYRCBOUKXJXDK-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010015958 Eye pain Diseases 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001500343 Influenzavirus C Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 229940124873 Influenza virus vaccine Drugs 0.000 description 1
- 241001500350 Influenzavirus B Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000710914 Totivirus Species 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000019666 ageusia Nutrition 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical group O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 210000000215 ciliated epithelial cell Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910052604 silicate mineral Inorganic materials 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses application of montmorillonite in preparing a medicament, in particular application of the montmorillonite in preparing a medicament for preventing and treating cold. The cold comprises common cold and influenza. A prepared pharmaceutical dosage form of the montmorillonite for preventing and treating the cold is a montmorillonite nose drop; a prepared pharmaceutical dosage form of the montmorillonite for preventing and treating the cold is a montmorillonite spray; and a prepared pharmaceutical dosage form of the montmorillonite for preventing and treating the cold is a montmorillonite aerosol. The invention has the advantages that the invention explores the novel use on pharmaceutical montmorillonite and develops a novel application field; the montmorillonite nose drop or the montmorillonite spray or the montmorillonite aerosol can prevent and treat the common cold and the influenza; the montmorillonite only acts on the upper respiratory tract, is not absorbed by an organism, and has no toxicity and side effect; viruses and bacteria do not produce the drug tolerance; and the advantages of easily-obtained raw materials, low cost and low treatment cost are obviously superior to medicaments which are commonly used for preventing and treating the influenza at present.
Description
Technical field
The present invention relates to the new purposes of Montmorillonitum, be specifically related to Montmorillonitum the application in preparation medicine of Montmorillonitum in prevention and treatment flu.
Background technology
At present, the application of Montmorillonitum in medicine all is by the digestive tract administration, mainly treats gastroenteropathy.The new purposes of the disclosed Montmorillonitum of Chinese patent of approval in 2007 is that treatment chronic renal failure disease also is to treat by the digestive tract administration, and up to the present, Shang Weiyou is by the report of other administering mode treatment diseases.
Montmorillonitum is the layer silicate mineral that typical 2: 1 types contain water of crystallization, has many good characteristics such as polymolecularity, suspension, swelling, caking property, adsorptivity, cation exchange.Montmorillonitum has a long history as medicinal, and oral back medicine can cover whole enteric cavity surface equably, has high stationkeeping ability, can keep 6 hours.Be used for the treatment of diarrhoea, adsorbable multiple pathogen of Montmorillonitum and digestive tract endotoxin are fixed in the enteric cavity surface, then excrete with enterokinesia, thereby avoid the damage to body of multiple pathogen and digestive tract endotoxin.
Put down in writing in China's the Tang Dynasty medical science masterpiece supplement to the Herbal: " Montmorillonitum is nontoxic, cures mainly medical herbs and all bacteriums, hot soup actuator end clothes ".Montmorillonitum is bentonite (main component is a Montmorillonitum), can be widely used in anxious, the slow property diarrhoea of treatment, treatment esophagitis, gastritis, colitis, irritable bowel syndrome.Because Montmorillonitum clothes back is difficult for absorbing, and does not enter blood circulation, and is fool proof during the application, non-toxic reaction, the clinical application that is used for the pediatric disease treatment is in recent years constantly widened.
For example: Chinese patent ZL200510082757.0 discloses the application of smectite in treatment chronic renal failure.Chinese patent ZL03121876.8 discloses the smectite in treatment hyperthyroidism, the application of halitosis etc.
Summary of the invention
The object of the present invention is to provide the application of Montmorillonitum in the preparation medicine, by the upper respiratory tract administration, prevent and the treatment flu, and the pharmacy type of catching a cold with Montmorillonitum prevention and treatment is provided, the method for prevention and treatment flu is provided simultaneously with Montmorillonitum.
For achieving the above object, be achieved through the following technical solutions: the application of Montmorillonitum in preparation prevention and treatment cold medicine.Montmorillonitum is the Montmorillonitum nasal drop at the pharmaceutical dosage form of preparation prevention and treatment flu, and Montmorillonitum is the Montmorillonitum spray at the pharmaceutical dosage form of preparation prevention and treatment flu, and Montmorillonitum is the Montmorillonitum aerosol at the pharmaceutical dosage form of preparation prevention and treatment flu.
Flu of the present invention comprises common cold and influenza.
Common cold is a kind of disease of slight and self limiting, is often caused by parainfluenza virus, rhinovirus, respiratory syncytial virus, Coxsackie virus and crown virus etc.The people is by the virulent secretions in contact environment surface, and the air that sucks the respiratory secretions that contains a large amount of viruses is infected.Virus is invaded people's upper respiratory tract, cause bacterial flora alternation that upper respiratory tract normally settles down and host inflammatory reaction, damaged host's airway epithelial and stromatin, make antibacterial invade just often aseptic zone, as nasal sinuses, middle ear and tracheal bronchus etc., make bacterial precipitation arrive these zones, add the damage with the mucosa cleaning action of blocking of these regional exports, cause the Secondary cases bacterial infection.The clinical manifestation of common cold, cardinal symptom are watery nasal discharge, nasal obstruction, sneeze, throat pain, headache and cough.Have low grade fever, other discomforts comprise that slight ophthalmalgia, olfactory sensation and ageusia, the stifled sense of ear, voice have rhinophonia.In about 1 week of the course of disease, about 1/4 patient can continue until for 2 weeks.Do not have real " healing " coldrex at present, mainly contain antihistaminic and nonsteroidal antiinflammatory drug, can well alleviate sneeze, watery nasal discharge, headache.Antihistaminic can cause that mouth, nose, larynx are dry, stomachache, diarrhoea, vomiting, untoward reaction such as drowsiness, dizzy.The nonsteroidal antiinflammatory drug great majority have the ill effect that suppresses hemopoietic function.The way of prevention common cold is: blocking propagation, note to isolate, and the contact stain thing is avoided in air sterillization, washes one's hands and avoids hands nose, trick to contact naturally; Nasal cavity uses the medicine blocking virus to invade the nasal mucosa cell.
Influenza is called for short influenza, is the acute respiratory infectious disease that is caused respectively by first, second, the third three type influenza virus.Influenza A virus often occurs with popular form, can cause global being very popular.Influenza B virus often causes the part to break out, and does not cause worldwide being very popular.Influenza virus C occurs to distribute form, mainly attacks infant, does not cause influenza pandemic.Influenza virus has only by nasal cavity just can cause a disease.Main by the air transmitted by droplets and direct contact, influenza virus is injected in the people does not then fall ill.The ciliated epithelial cell that virus is at first invaded nasal mucosa further advances people's trachea bronchus, does great damage at regional area, causes the extensive inflammation of upper respiratory tract in 1-2d.After the influenza infection a few cell, copy a large amount of virions, infect other cells after the release again, cause and infect diffusion.The clinical manifestation of influenza has that fear of cold, heating, body temperature can reach that 38-40 ℃, headache, unable, ophthalmalgia, whole body are listless and aching, nauseating, watery nasal discharge, nasal obstruction, sneeze etc., flush and bulbar conjunctiva hyperemia.The whole body poisoning symptom that influenza produces is that part virus and product thereof enter blood flow and cause because respiratory mucosa destroys.In the influenza prevention, also do not break through veritably so far.Influenza virus vaccine at present commonly used in the world be purification, multivalent inactivated vaccine.Current employed have 3 types, cuts both ways.1. (preparation simple, cause untoward reaction sometimes) of totivirus grain deactivation; 2. half cracked (can reduce untoward reaction, but preparation process being loaded down with trivial details); 3. subunit vaccine (safety is good, but the antibody response weak effect, the cost height).Vaccine strain needs in time to change with the antigenic variation of strains of influenza viruses, otherwise can't guarantee preventive effect.The medicine of treatment influenza has duplicating of amantadine and the rimantadine specific inhibition influenza A virus of energy at present, invalid to Influenza B virus, these two kinds of medicines all have common cross-sensitivity or drug resistance, and side effect is easily to produce neurotoxicity and easily produce drug resistance.Virazole confirms to resist the first type also can anti-Influenza B virus in experiment in vitro, but clinical no obvious antivirus action and therapeutic effect.
The present invention both can prevent simultaneously also can treat common cold and influenza, and life-time service does not produce drug resistance, and was nontoxic, have no side effect.
Montmorillonitum adds water make nasal drop or spray or aerosol after, Montmorillonitum is by intergranular osmotic swelling and intermediary water, Dispersion of Particles is peeled off between the lamination, electronegative aspect and end face interaction, crosslinked association formation aquation gel.Montmorillonitum aquation gel removes significant adhesiveness, can combine with the mucus on upper respiratory tract surface, significantly strengthens mucous cohesiveness and viscoelasticity, is covered in the nasal mucosa surface securely, forms isolation protection film, and effectively blocking virus is invaded the nasal mucosa cell.Use Montmorillonitum nasal drop or spray or aerosol, can reach the purpose of preventing cold.
After Montmorillonitum nasal drop or spray or aerosol enter upper respiratory tract, can cover whole upper respiratory tract surface, by adsorption and " card room formula " gel structure, the toxin that enters virus, pathogenic bacteria and their generations of upper respiratory tract can be adsorbed, fixes, then excrete with nasal mucus, make it lose pathogenic effects, and can suppress duplicating and propagating of virus.Use Montmorillonitum nasal drop or spray or aerosol, can reach the purpose of treatment flu.
Animal experiment and clinical data that the applicant makes with Montmorillonitum prevention and treatment flu are summarized as follows:
One, animal experiment report
The Montmorillonitum nasal drop is to the preventive and therapeutic effect of influenza virus A type (flu-A) infecting mouse
1, material
1.1 animal: Kunming mouse, the male and female dual-purpose, body weight 18-22 gram, credit number: SCXK (Shandong) 2005-0015 is provided by Shandong Traditional Chinese Medicine University's Experimental Animal Center.The raising condition: the plastic box bottom shop soft sawdust of one deck is raised, and male and female are divided foster, and 5 in every box is freely raised, and temperature is controlled at 20～25 ℃, the well-ventilated, and humidity 55～60% is normally raised all backs for examination.
1.2 influenza virus A type (flu-A): the local epidemic strain in nineteen ninety-five Beijing, drew from Chinese CDC virosis institute influenza virus chamber in 2004.Low temperature is frozen standby.Get seed culture of viruses before the experiment and dash with flowing water and melt, be diluted to per 0.05 milliliter of concentration that contains 15 LD50, put in the frozen water standby with physiological saline solution.
1.3 medicine: concentration is the Montmorillonitum nasal drop of 5%, 20%, 30% (g/ml), has Jinan Kangzhong Medicin Science ﹠ Technology Co., Ltd. to provide.Ba Weilin nasal drop (10 milliliters: 50 milligrams) is purchased the pharmacy in Hong Jitang.
2, method
2.1 grouping and administration: mice is divided into blank group, model group, Ribavirin Nasal Drops group and Montmorillonitum nasal drop 5%, 20%, 30% (g/ml) dosage group, totally 6 groups, 30 every group at random.Ribavirin Nasal Drops collunarium every day 3 times, each 0.05 milliliter.Montmorillonitum nasal drop collunarium every day 3 times, each 0.0 milliliter, blank group and model group give the normal saline of equivalent.1 week of successive administration.
2.2 viral infection: after the administration the 2nd day, except that the normal control group, each was organized mice and infects every (inferior) 0.05 milliliter with 15 LD50 influenza virus collunariums.
2.3 testing index
2.3.1 mouse death rate, the mice body weight of record different time is observed the mouse invasion symptom behind the infecting mouse, record mouse diing time and death toll.Observe every day, until infecting back 7d.
3, result
3.1 it is good respectively to organize the observation blank group mice mental status of experiment mice behavior state, alertness, and movable quick, hair is glossy, and diet is good, and eupnea, body weight increase naturally.The 1st day Non Apparent Abnormality symptom of model group mice.Asthenia was arranged on the 2nd day slightly, and it is in disorder that hair occurs, loss of gloss pool gradually, and rapid breathing is not liked activity, and is easily frightened.The 3rd day above-mentioned sx, beginning is dead, and the spasm symptom has a convulsion when dead.Ribavirin Nasal Drops group mice behind viral infection, occurred in the 3rd day hair in disorder, be slow in action, symptom such as rapid breathing, symptom disappears substantially after the 7th day, dead therebetween 3.Each concentration group of Montmorillonitum nasal drop 5%, 20%, 30% (g/ml) began to occur hair number of elements in disorder, that roll up, do not like symptoms such as activity, rapid breathing on the 3rd day behind viral infection be 10,5,3, other mice Non Apparent Abnormality symptoms, dead number of elements takes place each concentration group is 5,3,1.The results are shown in Table 1.
Table 1 Montmorillonitum nasal drop is to the control protective effect of influenza virus A type (flu-A) infecting mouse
3.2 the Montmorillonitum nasal drop is the Montmorillonitum nasal drop of 5%, 20%, 30% (g/ml) to the dead protective effect concentration of influenza virus A type (flu-A) infecting mouse, the dead protective rate of treatment influenza virus A type (flu-A) infecting mouse is respectively 50%, 40%, 66.7%.The dead protective rate of ribavirin collunarium group is 90%.The dead protective rate of model group is 23.3%.The results are shown in Table 2.
Table 2 Montmorillonitum nasal drop is to the dead protective effect of influenza virus A type (flu-A) infecting mouse
Presentation of results Montmorillonitum nasal drop has extraordinary prevention and therapeutical effect to influenza virus A type (flu-A) infecting mouse, can be used for prevention and treatment influenza.
Two, extracorporeal antivirus effect report
1, experiment purpose
Detect the effect of the external absorption inactivation of viruses of Montmorillonitum nasal drop.
2, experiment material
(1) test cell strain:
1. MDCK (influenza virus A type, influenza virus B virus strain host cell) drew from Chinese CDC virosis institute influenza virus chamber in 2004.
2. Hep-2 cell (respiratory syncytial virus host cell) drew the cell bank from basis institute of the Chinese Academy of Medical Sciences, these section office liquid nitrogen cryopreservation in 2002.
(2) test Strain:
1. influenza virus A type (flu-A): the local epidemic strain in nineteen ninety-five Beijing, drew from Chinese CDC virosis institute influenza virus chamber in 2004.
2. influenza virus B-mode (flu-B): the source background is with the influenza Alphavirus.
3. respiratory syncytial virus (RSV): drew in 1998 from Chinese CDC virosis institute seed culture of viruses storehouse, these section office preserve.
(3) given the test agent: the Montmorillonitum nasal drop, be the milky suspension, Jinan Kangzhong Medicin Science ﹠ Technology Co., Ltd. provides.Date of manufacture: 2009.9.20.
(4) testing equipment:
4.1 CO2 gas incubator: Thermo Forma company product, 3111 types.
4.2 liquid nitrogen container: elegance and talent machinery plant product, YD-30 type.
4.3 cell culture fluid: RPMI1640, GIBCO company product, the by specification preparation, adding 10% new-born calf serum is cell culture fluid, adding 2% new-born calf serum is cell maintenance medium.
4.4 phosphate normal saline: NaCL8g, KCL0.2g, KH2PO40.2g, Na2HPO4.12H2O adds distilled water to 100ml, 121 ℃ of 20min steam sterilizations.
4.5 cell dissociation buffer: containing 0.25% pancreatin, with the preparation of phosphate normal saline, is 0.2 micron filter filtration sterilization with the filtration diameter, deposits for-20 ℃.
4.6 cell dye liquor: 1% dimethyl diaminophenazine chloride.
4.7 destaining solution: the 0.05mol/L glacial acetic acid adds 50% ethanol
4.8 inverted microscope: OLYMPUS company product.
4.9 ultralow temperature refrigerator-freezer :-86 ℃, U.S. Thermo Forma company product.
3, method
(1) test basis: " medical virology basis and experimental technique ", " new drug (Western medicine) clinical research guideline ".
(2) detection method: cytopathy political reform
2.1 recovery, preparation Hep-2, MDCK cell monolayer: the cell pipe of liquid nitrogen cryopreservation is melted 37 ℃ of speed, the centrifugal 5min of 1000r/min, the aseptic condition supernatant that goes down, precipitation suspends with cell culture fluid, puts 37 ℃, 5%CO in the Tissue Culture Flask
2Cultivate under the condition, it is standby to grow up to monolayer after 3 days.
2.2 activation and proliferation virus: mdck cell and Hep-2 cell are inoculated in influenza virus A type, influenza virus that lyophilizing is preserved is B-mode, respiratory syncytial virus strain respectively, put 37 ℃, 5%CO with cell maintenance medium
2Cultivate under the condition, stop cultivating when 70% pathological changes appears in cell, incline gently and keep liquid, it is inferior to give a baby a bath on the third day after its birth with PBS, adding distil water 2ml freeze thawing 3 times, and the centrifugal 20min of 2000r/min abandons precipitation, and supernatant packing penicillin bottle is put-86 ℃ of refrigerators, virus virulence to be determined.
2.3 virus virulence is measured: viral liquid is done 10 multiple proportions serial dilutions, laterally be inoculated in successively on the cell monolayer in 96 orifice plates, every hole 100 μ l, identical dilution factor vertically repeat 3 holes and are provided with cell contrast and blank simultaneously.Putting 37 ℃, 5%CO2 constant incubator hatches, microscopically observation of cell pathological changes is as judge index, stop during 5d cultivating, with 37 ℃ of dyeing of 1% dimethyl diaminophenazine chloride 2h, wash 3 times with PBS and remove free dye, add 100 μ l destaining solution in every hole, read the absorbance A value with microplate reader at the 540nm place, 1. calculate cell survival rate with formula, calculate virus virulence with the Reed-Muench method then, use TCID
50/ ml represents.
Formula is 1.: cell survival rate (%)=(viral hole A value-blank hole A value)/(cell control well A value-blank hole A value) * 100%
2.4 the external deactivation of Montmorillonitum nasal drop detects:
2.4.1 external deactivation
With quantitative virus (influenza virus A type TCID
50/ ml is O
2/ mL, the B-mode TCID of influenza virus
50/ ml is 10
3/ mL, respiratory syncytial virus TCID
50/ ml is 10
5ML) 500 μ l are respectively with 20%.10%, capacity such as 5% Montmorillonitum nasal drop mixes, and 37 ℃, 5%CO2 constant incubator are hatched 60min, and each group sample is obtained supernatant with the centrifugal 10min of 2000r/min, carry out titration viral level (TCID with this paper 2.3 described methods respectively then
50/ mL), parallel virus control group, positive drug matched group (ribavirin), normal cell matched group, the drug toxicity matched group of being provided with.By more viral TCID between group
50/ ml index variation judges that the Montmorillonitum nasal drop adsorbs deactivation to virus.
4, result
(1) virus virulence is measured:
Influenza virus A type, influenza virus are B-mode, respiratory syncytial virus TCID50/mL is respectively: 10
2/ mL, 10
3/ mL, 10
10/ mL.
(2) take off stone nasal drop absorption inactivation of viruses effect monitoring
Behind the Montmorillonitum nasal drop and virus function 1h with variable concentrations, viral level significantly reduces in its supernatant, sees Table 1.
Table 1 Montmorillonitum is to the influence of viral infection virulence TCID50
Annotate: in the bracket be and the more viral TCID50 decline of virus control group index
Can find out obviously that from last table the Montmorillonitum nasal drop of variable concentrations (20%, 10%, 5%) is B-mode to influenza virus A type, influenza virus, respiratory syncytial virus all has the good adsorption deactivation, through at 37 ℃, 5%CO
2Constant incubator is hatched 60min, flu-ATCID50 1 index that descends respectively, flu-B 3 indexes that descend, RSV 5 indexes that descend.Show that the Montmorillonitum nasal drop of 20%, 10%, 5% variable concentrations all has the effect of powerful viral adsorption.
5, conclusion
After testing, the Montmorillonitum nasal drop has direct adsorption and sedimentation deactivation to influenza A virus, Influenza B virus, respiratory syncytial virus virus.Can be used for prevention and treatment flu.
Three, treat grippal clinical effectiveness statistics with Montmorillonitum spray and nasal drop:
Volunteer's 461 examples, (1) have flu patient contact history; (2) febris acuta, fear of cold, the dried pain of itching of bottleneck throat appear, with other symptoms such as cough, nasal obstruction watery nasal discharges; (3) check pharyngeal obvious hyperemia or antiadoncus, hyperemia; (4) blood testing checks that numeration of leukocyte is normal or on the low side, and percentage of lymphocyte raises; (5) get rid of the infection at other position.
114 routine patients contain Montmorillonitum sprays that montmorillonite 20 restrain with per 100 milliliters Montmorillonitum spray, the 62 routine patients that contain Montmorillonitum 15 grams with per 100 milliliters with per 100 milliliters Montmorillonitum spray, the 77 routine patients that contain Montmorillonitum 10 grams, the patient is sprayed medicine and preceding sparing nasal cavity is cleaned out, the nozzle of medicine bottle is inserted the nostril, each every nostril 1? spray, 0.2 milliliter of every spray, spray 2-4 every day.Need explanation: 5 routine patients contain the Montmorillonitum sprays that Montmorillonitum 5 restrains with 100 milliliters, and Therapeutic Method is same as described above, but every day, 3 sprays must be sprayed in every nostril, and 0.2 milliliter of every spray must be sprayed 4 every day.
92 routine patients contain Montmorillonitum nasal drop that montmorillonite 20 restrain with per 100 milliliters Montmorillonitum nasal drop, the 36 routine patients that contain Montmorillonitum 10 grams with per 100 milliliters with per 100 milliliters Montmorillonitum nasal drop, the 80 routine patients that contain Montmorillonitum 15 grams, before the medication, earlier nasal cavity is cleaned out, head back tilts to make the nostril up, medicine is splashed into the nostril, does each nostril all drip 2? spray, every 0.06 milliliter, drip 2-4 every day, after splashing into, pinches medicinal liquid the wing of nose for several times, and kept the nostril 5 minutes up, medicine is fully contacted with bronchia mucosal.The result: 242 examples of fully recovering, produce effects 173 examples, effective 45 examples, effective percentage is 100%.
The preventing cold statistics:
Volunteer's 37 examples, the age is 25-31 year, 6 people, 37-41 year, 4 people, 49-62 year, 27 people; The experimenter is climate change whenever, must catch a cold, whenever contact with the flu patient, must be infected, annual times of common cold is disregarded, use per 100 milliliters to contain Montmorillonitum 8 gram nasal drop 1 year, every day twice, each nostril is each two at every turn, every 0.0625 milliliter, 1 year experimenter of tracing observation does not have an example to catch a cold, and illustrates that Montmorillonitum nasal drop preventing cold is respond well.
As well known to those skilled in the art, Montmorillonitum nasal drop or spray or aerosol, preparation technology's basically identical, just be sub-packed in different containers at last, obtain different dosage forms, enter nasal cavity or upper respiratory tract after, 3 kinds of dosage forms all are smectite turbid liquors, and its clinical effectiveness should be consistent.
In sum, summary of benefits of the present invention comprises following several respects:
(1) the present invention has excavated new purposes to medicinal smectite, has opened up a new application.
(2) Montmorillonitum nasal drop or spray or aerosol not only can prevent but also can treat common cold and influenza.
(3) Montmorillonitum only acts on upper respiratory tract, and body does not absorb, and is nontoxic, has no side effect.
(4) virus and antibacterial do not produce drug resistance.
(5) raw material is easy to get, and is cheap, and the treatment cost is low, and above-mentioned advantage obviously is better than the grippal medicine of control commonly used at present.
The specific embodiment
The application of Montmorillonitum in preparation prevention and treatment cold medicine, flu comprises common cold and influenza.Montmorillonitum is the Montmorillonitum nasal drop at the pharmaceutical dosage form of preparation prevention and treatment flu, and Montmorillonitum is the Montmorillonitum spray at the pharmaceutical dosage form of preparation prevention and treatment flu, and Montmorillonitum is the Montmorillonitum aerosol at the pharmaceutical dosage form of preparation prevention and treatment flu.
Adopt Montmorillonitum to prepare spray and nasal drop, be used for the treatment of first type, B-mode and acute respiratory infectious disease that influenza virus C causes.
Method with prevention of Montmorillonitum spray and treatment flu is: patient's nasal cavity is cleaned out, head keeps angle perpendicular to the ground or that turn forward, the nozzle of Montmorillonitum medicine spray container is inserted nasal cavity, each nostril is the 1-3 spray at every turn, each spray 0.1-0.2 milliliter, spray 2-4 every day.
Method with prevention of Montmorillonitum nasal drop and treatment flu is: patient's nasal cavity is cleaned out, head back tilts to make the nostril up, medicine is splashed into the nostril, each nostril is all dripped 2-3 and is dripped, every 0.0625 milliliter, drip 2-4 every day, pinches the wing of nose after medicinal liquid splashes into for several times, and kept the nostril 5 minutes up, medicine is fully contacted with bronchia mucosal.
Montmorillonitum is in the application that is used for preventing and treating flu, and its medicament is to be main dosage form with nasal drop and spray, also can make aerosol.Smectite content is per 100 milliliters and contains Montmorillonitum 5-20 gram in the various drug forms.
Montmorillonitum nasal drop, spray and aerosol all are principal agent with the Montmorillonitum, add medical auxiliary materials, add water and make per 100 milliliters of Montmorillonitum nasal drop, Montmorillonitum spray or Montmorillonitum aerosols that contain Montmorillonitum 5-20 gram.Used medical auxiliary materials is medical nasal drop, spray or aerosol adjuvant commonly used.
Illustrate the preparation method of three kinds of dosage forms below:
Embodiment 1 preparation Montmorillonitum nasal drop
Take by weighing Montmorillonitum 50 gram, agar 5 grams add deionized water to 1000 milliliter, stir, and again with the mixed liquor that stirs, become the uniform liquid of Montmorillonitum fineness of the particles less than 20 μ m with milling treatment of colloid, through cobalt
60Radiation sterilization, packing promptly get per 100 milliliters of Montmorillonitum nasal drop that contain Montmorillonitum 5 grams.
Embodiment 2 preparation Montmorillonitum nasal drop
Take by weighing Montmorillonitum 100 grams, methylcellulose 10g, add normal saline to 1000 milliliter, stir, again with the mixed liquor that stirs, supersound process becomes the uniform liquid of Montmorillonitum fineness of the particles less than 45 μ m, and packing promptly gets per 100 milliliters of Montmorillonitum nasal drop that contain Montmorillonitum 10 grams after boiling sterilization in 15 minutes.
Embodiment 3 preparation Montmorillonitum nasal drop
Take by weighing montmorillonite 2 00 gram, add entry to 1000 milliliter, stir, promptly get per 100 milliliters and contain montmorillonite 20 and restrain the Montmorillonitum nasal drop through boiling sterilization back packing in 20 minutes.
Embodiment 4 preparation Montmorillonitum sprays
Take by weighing Montmorillonitum 80 grams, sodium benzoate 1.5 gram adds entry to 1000 milliliter, stir, again with the liquid that stirs, become the uniform liquid of Montmorillonitum fineness of the particles with milling treatment of colloid less than 10 μ m, after boiling sterilization in 20 minutes, be sub-packed in the spray bottle, promptly get per 100 milliliters of Montmorillonitum sprays that contain Montmorillonitum 8 grams.
Embodiment 5 preparation Montmorillonitum aerosols
Take by weighing Montmorillonitum 150 grams, nipalgin 2 gram adds entry to 1000 milliliter, stir, with the liquid that stirs, become the uniform liquid of Montmorillonitum fineness of the particles again, after boiling sterilization in 20 minutes less than 10 μ m with milling treatment of colloid, be sub-packed in container, the dress valve rolls tightly, is pressed into propellant, promptly gets per 100 milliliters of Montmorillonitum aerosols that contain Montmorillonitum 15 grams.
Claims (4)
1. the application of Montmorillonitum in the preparation medicine is characterized in that: the application in preparation prevention and treatment cold medicine.
2. the application of Montmorillonitum according to claim 1 in the preparation medicine is characterized in that: the pharmaceutical dosage form of preparation prevention and treatment flu is the Montmorillonitum nasal drop.
3. the application of Montmorillonitum according to claim 1 in the preparation medicine is characterized in that: the pharmaceutical dosage form of preparation prevention and treatment flu is the Montmorillonitum spray.
4. the application of Montmorillonitum according to claim 1 in the preparation medicine is characterized in that: the pharmaceutical dosage form of preparation prevention and treatment flu is the Montmorillonitum aerosol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910308592A CN101690729A (en) | 2009-09-09 | 2009-10-21 | Application of montmorillonite in preparing medicament |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910018651.2 | 2009-09-09 | ||
| CN200910308592A CN101690729A (en) | 2009-09-09 | 2009-10-21 | Application of montmorillonite in preparing medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101690729A true CN101690729A (en) | 2010-04-07 |
Family
ID=42079479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910308592A Pending CN101690729A (en) | 2009-09-09 | 2009-10-21 | Application of montmorillonite in preparing medicament |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101690729A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011029218A1 (en) * | 2009-09-09 | 2011-03-17 | 济南康众医药科技开发有限公司 | Use of montmorillonite in manufacture of medicaments |
| CN102526095A (en) * | 2012-02-14 | 2012-07-04 | 济南康众医药科技开发有限公司 | Medicinal composition for treating catarrh |
| CN102579481A (en) * | 2012-03-30 | 2012-07-18 | 济南康众医药科技开发有限公司 | Medicinal composition for treating catarrh symptom |
-
2009
- 2009-10-21 CN CN200910308592A patent/CN101690729A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011029218A1 (en) * | 2009-09-09 | 2011-03-17 | 济南康众医药科技开发有限公司 | Use of montmorillonite in manufacture of medicaments |
| CN102526095A (en) * | 2012-02-14 | 2012-07-04 | 济南康众医药科技开发有限公司 | Medicinal composition for treating catarrh |
| CN102579481A (en) * | 2012-03-30 | 2012-07-18 | 济南康众医药科技开发有限公司 | Medicinal composition for treating catarrh symptom |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101784272A (en) | Antiviral composition comprising a sulfated polysaccharide | |
| CN115721726B (en) | Nasal product for preventing or relieving cold symptoms and preparation method thereof | |
| CN106794198A (en) | Use the treatment and prevention of the common cold of PVP-I | |
| CN103028001B (en) | It is a kind of be used for relieving asthma, the Chinese prescription of antibechic, anti-inflammatory, Its Preparation Method And Use | |
| CN111358929A (en) | New application of small bupleurum particles in inhibiting influenza A virus | |
| CN101690729A (en) | Application of montmorillonite in preparing medicament | |
| CN102641356B (en) | Traditional Chinese medicine composition for treating respiratory tract viral infectious diseases and preparation method thereof | |
| CN105998599A (en) | Traditional Chinese medicine composition for treating viral respiratory tract infection and preparation method thereof | |
| TWI453026B (en) | Use of anisomeles indica (l.) kuntze extract and purified products thereof against influenza virus | |
| CN111388421A (en) | Oral-nasal-throat bi-component spray with antibacterial and antiviral functions and preparation method thereof | |
| CN102988469A (en) | Traditional Chinese medicine composition for preventing and treating influenza virus infection as well as preparation method and application thereof | |
| CN102940708A (en) | Traditional Chinese medicine chewable tablet for treating upper respiratory tract infection and preparation method of chewable tablet | |
| Khan et al. | Understanding and combating COVID-19 using the biology and chemistry of SARS-CoV-2 | |
| RU2353376C1 (en) | Method of bronchial pneumonia treatment and prevention in calves and piglets | |
| CN102198192B (en) | Traditional Chinese medicine composition for treating HINI and application thereof | |
| Roy et al. | Nanomaterials and Bioactive Compounds against SARS‐CoV‐2 | |
| WO2011029218A1 (en) | Use of montmorillonite in manufacture of medicaments | |
| CN105902534B (en) | Phenol boheic acid element treats or prevents the application in medicament for treating respiratory system object in preparation | |
| CN100393358C (en) | Preparation of horse family animal anti human, pultry grippe immune globulin and its medicinal preparation | |
| CN106237050A (en) | A kind of Chinese medicine compound of effective preventing and treating H1N1 and H3N2 swine flue and pig blue-ear disease and preparation method thereof | |
| CN107982356A (en) | A kind of oral drugs for treating respiratory tract infection | |
| CN100493605C (en) | Application of human lysozyme in preparation of anti-influenza virus medicine | |
| CN105943540A (en) | Application of simiarenol | |
| CN114146082A (en) | Application of methylparaben and sodium salt thereof in resisting coronavirus | |
| CN106336447B (en) | The application of celastrin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100407 |